Sun Pharma announced that the US FDA has granted a tentative approval for an Abbreviated New Drug Application (ANDA) for generic Strattera, atomoxetine hydrochloride capsules.

These atomoxetine hydrochloride capsules, therapeutically equivalent to Strattera capsules from Eli Lilly, are available in seven strengths viz. 10 mg, 18 mg, 25 mg, 40 mg, 60 mg, 80 mg and 100 mg. Atomoxetine hydrochloride capsules have annual sales of approximately USD 500 million in the US.

Strattera capsules are indicated for the treatment of attention deficit hyperactivity disorder.

Strattera is a registered trademark of Eli Lilly and Company.